Immunotherapy News and Research

Latest Immunotherapy News and Research

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

Scientists identify mechanism that may help prostate cancer cells escape effects of cancer drugs

Advanced prostate cancer is a disease notoriously resistant to treatment. New research by scientists at Fred Hutchinson Cancer Research Center and the University of California, San Francisco sheds light on a new mode of drug resistance to emerging therapies in metastatic prostate cancer.

18 Nov 2015

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer.

18 Nov 2015

NSU collaborates with Karolinska Institutet to conduct cell-based biomedical research

Nova Southeastern University is now at the forefront of conducting pioneering cell-based biomedical research with the launch of the new NSU Cell Therapy Institute, an international collaboration with prominent medical research scientists from Sweden's world-renowned Karolinska Institutet (KI).

17 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Researchers identify new target for novel immune-oncology treatments

By studying a type of immune cells, a team of researchers at the IRCM led by André Veillette, MD, identified the mechanism of action for a new target for novel immune-oncology treatments. Their discovery is published today in the print edition of the scientific journal the Journal of Experimental Medicine.

17 Nov 2015

Loyola and Notre Dame researchers report promising new approaches to treating cancer

Promising new approaches to treating cancer were reported during a recent meeting of researchers from Loyola University Chicago and the University of Notre Dame.

12 Nov 2015

Moffitt Cancer Center study finds link between common gene mutations and tumor immune surveillance

Learning if a lung cancer patient has genetic mutations can help oncologists determine the best approach to treatment. There are four gene mutations (KRAS, TP53, STK11, and EGFR) that most commonly occur in lung cancer; however, there are limited effective therapies to target these mutations. With this in mind, Moffitt Cancer Center performed an extensive genetic analysis of lung cancer specimens to unravel how mutations in the two of those genes (TP53 and STK11) contribute to the biology of lung cancer and patient outcomes.

12 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Possible reasons found for Alzheimer’s treatment failure

Agglutinated proteins in the brain, known as amyloid-β plaques, are a key characteristic of Alzheimer’s. One treatment option uses special antibodies to break down these plaques.

10 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

NanoString Technologies, Inc.a provider of life science tools for translational research and molecular diagnostic products, today announced the expansion of its 3D Biology™ portfolio with the commercial launch of the nCounter® PanCancer Profiles, seven new gene expression panels each designed to interrogate a focused area of cancer biology including immuno-oncology.

9 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Allergic response can be unexpected clue in medical mystery

Most people think of allergists as the doctors who help solve sneezing, wheezing and itchy eyes. They might not realize allergists are the medical mystery detectives with the expertise to discover what is causing all sorts of unusual allergic responses.

6 Nov 2015

Specific gut bacteria can improve cancer immunotherapy, show studies

By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells. T

6 Nov 2015

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.

6 Nov 2015

Majority of people not allergic to intravenous penicillins, say ACAAI allergists

Most people who think they're allergic to penicillin have been told so by a doctor after they've had a reaction to the drug. And the majority, even though they've never been allergy tested, never take penicillin again.

6 Nov 2015

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Hot flashes. Night sweats. These are the most common - or at least the most commonly talked about - symptoms of menopause. But one reality of The Change for many women is less discussed yet no less important: problems with vaginal health and sexual function.

6 Nov 2015

Researchers uncover important mechanism that could help protect against infection, allergy and cancer

New research has uncovered an important mechanism in the drive to understand immunological processes that protect us against infection, allergy and cancer.

5 Nov 2015

Researchers discover potential solution for side effects of immunotherapy treatment for Alzheimer's

It is estimated that 46.8 million people worldwide are living with dementia, with Alzheimer's disease the most common form.

5 Nov 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Lilly, Merck expand oncology clinical trial collaboration

Scientists identify mechanism that may help prostate cancer cells escape effects of cancer drugs

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

NSU collaborates with Karolinska Institutet to conduct cell-based biomedical research

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Researchers identify new target for novel immune-oncology treatments

Loyola and Notre Dame researchers report promising new approaches to treating cancer

Moffitt Cancer Center study finds link between common gene mutations and tumor immune surveillance

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Possible reasons found for Alzheimer’s treatment failure

New funding for Centenary's life saving research

Seven new nCounter PanCancer profiles launched to deeply probe cancer biology

Viralytics enters into clinical trial collaboration agreement with MSD

Allergic response can be unexpected clue in medical mystery

Specific gut bacteria can improve cancer immunotherapy, show studies

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

Majority of people not allergic to intravenous penicillins, say ACAAI allergists

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Researchers uncover important mechanism that could help protect against infection, allergy and cancer

Researchers discover potential solution for side effects of immunotherapy treatment for Alzheimer's

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in